Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9968466 | 0.83 | CYP11B1 (0.46) | CRHBPCRHR2ALDH1A1CRBNCYP11B1 | |
| SCHEMBL14359443 | 0.79 | CYP11B1 (0.43) | CRBNCYP11B1CYP11B2 | |
| SCHEMBL16189944 | 0.76 | — | — | |
| SCHEMBL12243268 | 0.75 | CYP11B1 (0.44) | CRBNCYP11B1CYP11B2 | |
| SCHEMBL24629789 | 0.72 | CRBN (0.37) | CRBNCYP11B1CYP11B2 | |
| SCHEMBL24235261 | 0.72 | CYP11B1 (0.39) | CRBNCYP11B1CYP11B2 | |
| SCHEMBL22914739 | 0.71 | CRBN (0.43) | CRBNCYP11B1CYP11B2 | |
| SCHEMBL16609890 | 0.71 | CRBN (0.39) | CRBNCYP11B1CYP11B2 | |
| SCHEMBL27256615 | 0.71 | SMN1; SMN2 (0.38) | ALDH1A1CRBNCYP11B1CYP11B2 | |
| SCHEMBL10166270 | 0.69 | CRHBP (0.42) | CRHBPCRHR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018015-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230192713-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192713-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | CD274, PDCD1LG2, PDCD1 | CRHBP 2287/4885CRHR2 3851/4885ALDH1A1 301/4885 |
| US-12018015-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | CRHBP 2287/4885CRHR2 3851/4885ALDH1A1 301/4885 |
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | CRHBP 2287/4885CRHR2 3851/4885ALDH1A1 301/4885 |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | AKT2, MTOR, AKT1 | CRHBP 3760/4885CRHR2 3553/4885ALDH1A1 4322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.